After digesting the setback of sarizotan in Rett syndrome, Newron is close to start two pivotal evenamide trials in schizophrenia and the Xadago pivotal trial in PD-LID, unlocking substantial equity upside. Newron is trading well below the value of its approved drug Xadago with no value contributed to its pipeline.
Key catalysts include:
1. Results evenamide “Study 008A” (end 2021)
2. Start pivotal trials evenamide in schizophrenia/CTRS (Q1 2022)
3. Start new label trial Xadago in PD-LID (Q1 2022)